O	0	6	Social
O	7	16	cognitive
O	17	27	influences
O	28	30	on
B-intervention	31	39	physical
I-intervention	40	48	activity
O	49	62	participation
O	63	65	in
O	66	70	long
O	70	71	-
O	71	75	term
O	76	82	breast
O	83	89	cancer
O	90	99	survivors
O	99	100	.

O	101	109	Although
O	110	118	physical
O	119	127	activity
O	128	130	is
O	131	141	beneficial
O	142	145	for
O	146	152	breast
O	153	159	cancer
O	160	169	survivors
O	169	170	,
O	171	174	the
O	175	183	majority
O	184	186	do
O	187	190	not
O	191	195	meet
O	196	202	public
O	203	209	health
O	210	218	physical
O	219	227	activity
O	228	243	recommendations
O	243	244	.

O	245	248	The
O	249	256	purpose
O	257	259	of
O	260	264	this
O	265	270	study
O	271	274	was
O	275	277	to
O	278	282	test
O	283	284	a
O	285	291	social
O	292	301	cognitive
O	302	308	theory
O	309	314	model
O	315	317	of
O	318	326	physical
O	327	335	activity
O	336	344	behavior
O	345	347	in
O	348	349	a
O	350	356	sample
O	357	359	of
B-eligibility	360	364	long
I-eligibility	364	365	-
I-eligibility	365	369	term
I-eligibility	370	376	breast
I-eligibility	377	383	cancer
I-eligibility	384	393	survivors
O	394	399	using
O	400	404	both
O	405	409	self
O	409	410	-
O	410	416	report
O	417	420	and
O	421	430	objective
O	431	439	measures
O	440	442	of
O	443	451	physical
O	452	460	activity
O	460	461	.

O	462	474	Participants
O	475	476	(
O	476	477	N
O	478	479	=
B-total-participants	480	484	1527
O	484	485	)
O	486	495	completed
O	496	504	measures
O	505	507	of
O	508	516	physical
O	517	525	activity
O	525	526	,
O	527	531	self
O	531	532	-
O	532	540	efficacy
O	540	541	,
O	542	547	goals
O	547	548	,
O	549	556	outcome
O	557	569	expectations
O	569	570	,
O	571	578	fatigue
O	578	579	,
O	580	583	and
O	584	590	social
O	591	598	support
O	599	601	at
O	602	610	baseline
O	611	614	and
O	615	616	6
O	616	617	-
O	617	622	month
O	623	629	follow
O	629	630	-
O	630	632	up
O	632	633	.

O	634	635	A
O	636	645	subsample
O	646	647	(
O	647	648	n
O	649	650	=
B-total-participants	651	654	370
O	654	655	)
O	656	659	was
O	660	668	randomly
O	669	677	selected
O	678	680	to
O	681	685	wear
O	686	688	an
O	689	702	accelerometer
O	702	703	.

O	704	706	It
O	707	710	was
O	711	723	hypothesized
O	724	728	that
O	729	733	self
O	733	734	-
O	734	742	efficacy
O	743	751	directly
O	752	755	and
O	756	766	indirectly
O	767	777	influences
O	778	786	physical
O	787	795	activity
O	796	803	through
O	804	809	goals
O	809	810	,
O	811	817	social
O	818	825	support
O	825	826	,
O	827	834	fatigue
O	834	835	,
O	836	839	and
O	840	847	outcome
O	848	860	expectations
O	860	861	.

O	862	875	Relationships
O	876	880	were
O	881	889	examined
O	890	895	using
O	896	901	panel
O	902	910	analysis
O	911	917	within
O	918	919	a
O	920	930	covariance
O	931	939	modeling
O	940	949	framework
O	949	950	.

O	951	954	The
O	955	967	hypothesized
O	968	973	model
O	974	982	provided
O	983	984	a
O	985	989	good
O	990	995	model
O	995	996	-
O	996	1000	data
O	1001	1004	fit
O	1005	1006	(
O	1006	1007	χ
O	1007	1008	(
O	1008	1009	2
O	1009	1010	)
O	1012	1013	=
O	1014	1018	1168
O	1018	1019	.
O	1019	1021	73
O	1021	1022	,
O	1023	1025	df
O	1026	1027	=
O	1028	1031	271
O	1031	1032	,
O	1033	1034	p
O	1035	1036	=
O	1037	1038	<
O	1038	1039	0
O	1039	1040	.
O	1040	1043	001
O	1043	1044	,
O	1045	1048	CFI
O	1049	1050	=
O	1051	1052	0
O	1052	1053	.
O	1053	1055	96
O	1055	1056	,
O	1057	1061	SRMR
O	1062	1063	=
O	1064	1065	0
O	1065	1066	.
O	1066	1068	04
O	1068	1069	)
O	1070	1072	in
O	1073	1076	the
O	1077	1081	full
O	1082	1088	sample
O	1089	1093	when
O	1094	1105	controlling
O	1106	1109	for
O	1110	1120	covariates
O	1120	1121	.

O	1122	1124	At
O	1125	1133	baseline
O	1133	1134	,
O	1135	1139	self
O	1139	1140	-
O	1140	1148	efficacy
O	1149	1157	directly
O	1158	1161	and
O	1162	1172	indirectly
O	1172	1173	,
O	1174	1177	via
O	1178	1183	goals
O	1183	1184	,
O	1185	1192	outcome
O	1193	1205	expectations
O	1205	1206	,
O	1207	1210	and
O	1211	1217	social
O	1218	1225	support
O	1225	1226	,
O	1227	1237	influenced
O	1238	1246	physical
O	1247	1255	activity
O	1255	1256	.

O	1257	1262	These
O	1263	1276	relationships
O	1277	1281	were
O	1282	1286	also
O	1287	1296	supported
O	1297	1303	across
O	1304	1308	time
O	1308	1309	.

O	1310	1322	Additionally
O	1322	1323	,
O	1324	1327	the
O	1328	1340	hypothesized
O	1341	1346	model
O	1347	1350	was
O	1351	1360	supported
O	1361	1363	in
O	1364	1367	the
O	1368	1377	subsample
O	1378	1382	with
O	1383	1396	accelerometer
O	1397	1401	data
O	1402	1403	(
O	1403	1404	χ
O	1404	1405	2
O	1406	1407	=
O	1408	1411	656
O	1411	1412	.
O	1412	1414	88
O	1414	1415	,
O	1416	1418	df
O	1419	1420	=
O	1421	1424	330
O	1424	1425	,
O	1426	1427	p
O	1428	1429	<
O	1430	1431	0
O	1431	1432	.
O	1432	1435	001
O	1435	1436	,
O	1437	1440	CFI
O	1441	1442	=
O	1443	1444	0
O	1444	1445	.
O	1445	1447	95
O	1447	1448	,
O	1449	1453	SRMR
O	1454	1455	=
O	1456	1457	0
O	1457	1458	.
O	1458	1460	05
O	1460	1461	)
O	1461	1462	.

O	1463	1467	This
O	1468	1473	study
O	1474	1483	validates
O	1484	1485	a
O	1486	1492	social
O	1493	1502	cognitive
O	1503	1508	model
O	1509	1512	for
O	1513	1526	understanding
O	1527	1535	physical
O	1536	1544	activity
O	1545	1553	behavior
O	1554	1556	in
O	1557	1561	long
O	1561	1562	-
O	1562	1566	term
O	1567	1573	breast
O	1574	1580	cancer
O	1581	1590	survivors
O	1590	1591	.

O	1592	1598	Future
O	1599	1606	studies
O	1607	1613	should
O	1614	1616	be
O	1617	1625	designed
O	1626	1628	to
O	1629	1638	replicate
O	1639	1643	this
O	1644	1649	model
O	1650	1652	in
O	1653	1658	other
O	1659	1665	breast
O	1666	1672	cancer
O	1673	1681	survivor
O	1682	1693	populations
O	1693	1694	,
O	1695	1698	and
O	1699	1702	the
O	1703	1711	findings
O	1712	1718	should
O	1719	1721	be
O	1722	1729	applied
O	1730	1732	to
O	1733	1736	the
O	1737	1748	development
O	1749	1751	of
O	1752	1758	future
O	1759	1767	physical
O	1768	1776	activity
O	1777	1785	programs
O	1786	1789	and
O	1790	1797	studies
O	1798	1801	for
O	1802	1806	this
O	1807	1817	population
O	1817	1818	.
